Secondary Logo

Ageing with HIV in South Africa

Hontelez, Jan A.C.a,b,c; Lurie, Mark N.d; Newell, Marie-Louisec; Bakker, Roela; Tanser, Frankc; Bärnighausen, Tillc,e; Baltussen, Robb; de Vlas, Sake J.a

doi: 10.1097/QAD.0b013e32834982ea
Research Letters
Free
SDC

We used an established microsimulation model, quantified to a rural South African setting with a well developed antiretroviral treatment programme, to predict the impact of antiretroviral therapy on the HIV epidemic in the population aged over 50 years. We show that the HIV prevalence in patients aged over 50 years will nearly double in the next 30 years, whereas the fraction of HIV-infected patients aged over 50 years will triple in the same period. This ageing epidemic has important consequences for the South African healthcare system, as older HIV patients require specialized care.

Supplemental Digital Content is available in the text

aDepartment of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam

bNijmegen International Center for Health System Analysis and Education, Department of Primary and Community Care, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

cAfrica Centre for Health and Population Studies, University of KwaZulu-Natal, Mtubatuba, South Africa

dDepartment of Community Health and the International Health Institute, Warren Alpert Medical School, Brown University, Providence, Rhode Island

eDepartment of Global Health and Population, Harvard School of Public Health, Boston, Massachusetts, USA.

Correspondence to Jan A.C. Hontelez, Department of Public Health, Erasmus MC, University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands.Tel: +31 30 704 46 32; e-mail: j.hontelez@erasmusmc.nl

Received 1 April, 2011

Revised 24 May, 2011

Accepted 3 June, 2011

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website ().

Antiretroviral therapy (ART) is changing the character of the HIV epidemic in sub-Saharan Africa. At the individual level, ART has increased survival of those infected. At the population level, widespread availability of ART could result in the overall ageing of the infected population. ART use in sub-Saharan Africa is expanding rapidly, with an estimated 3.9 million patients on treatment in 2009 [1]. Estimates show that there are already about 3 million people over 50 years living with HIV in sub-Saharan Africa [2]. Recently, Mills et al.[3] argued for more attention to be paid to HIV-infected older people in terms of prevention and care. In the USA, estimates from the Centers for Disease Control (CDC) show that about 29% of the entire population living with HIV was aged over 50 years in 2008 [4], and projections show that, in about 5 years time, more than half of all HIV-infected patients will be aged over 50 years [5]. Although it is clear that the number of HIV-infected elderly (aged over 50 years) in sub-Saharan Africa will rise as a result of the ART roll-out, the magnitude of this phenomenon has not yet been quantified. One of the countries most likely to be confronted with this shifting epidemic is South Africa, where nearly 6 million people are estimated to be HIV-infected, of whom 970 000 were on ART in 2009 [6]. HIV prevalence in the population aged over 50 years in South Africa is estimated at about 9% [2,7].

To predict the impact of the current ART roll-out on age-specific and sex-specific HIV prevalences in South Africa up to 2040, we used an established mathematical model (STDSIM) that simulates individuals in a dynamic network of sexual contacts [8,9]. The model is tailored to the Hlabisa sub-district in KwaZulu-Natal, South Africa (Supplementary Digital Content, http://links.lww.com/QAD/A150). This area has a high HIV prevalence [10] and a well developed ART programme [11,12]. In the model, the survival of ART-naive HIV-infected patients is on average 10 years. We assumed ART to increase survival from start of treatment by a factor of 3 and decrease infectivity by 92%, as observed in recent studies [13,14]. We assumed ART to be initiated at CD4 cell counts of 200 cells/μl or less in the period 2004–2010 and 350 cells/μl or less in 2011, according to the new WHO guidelines [15]. The model contains an age-specific partner change rate, as well as frequency of intercourse within a sexual relationship. In previous applications of our model [9], decreasing trends of sexual activity by age in the population aged 15–49 years were simply extrapolated to the over-50 years group because of a lack of available data on sexual behaviour in the population aged over 50 years. This resulted in a negligible level of risk behaviour and HIV incidence in the over-50 years group, which is inconsistent with recent local data in terms of HIV prevalence in this group [7]. Therefore, we now assumed partner acquisition rates to remain at the same level from age 45 years onwards, whereas the frequency of sexual contacts within a relationship is reduced by 25% for those aged over 50 years. The ART roll-out in Hlabisa is part of the South African national ART roll-out aimed at achieving universal coverage. Therefore, we assume that the impact of ART on the course of the epidemic is not affected by migration.

Figure 1a shows the projected trends in HIV prevalence in the population aged 15–49 years and over 50 years in Hlabisa. Whereas HIV prevalence in the 15–49 years group would more than halve in the period 2010–2040 from 28 to 9%, the HIV prevalence in the population aged 50 years and older is estimated to nearly double in the same period, from about 9% (8% in women; 11% in men) to 17% (16% in women; 17% in men). The total number of HIV infections in those aged over 50 years is expected to have increased by 51% in 2025 (49% for men; 53% for women), after which the number of HIV infections in this age group remains relatively stable (Fig. 1b). The absolute number of HIV infections in the elderly is estimated to even have doubled by 2025 compared to 2004, the year the ART roll-out in the area started. As a result, the age distribution of HIV-infected patients would change considerably (Fig. 1c). This is especially true for men, in which case currently less than one in 12 HIV-infected people is aged over 50 years; in 2040, this would be one in four.

Fig. 1

Fig. 1

We show that the number of HIV-infected elderly will increase substantially over the coming decades. This will further complicate an ongoing epidemiological transition in South Africa, where projections show that, despite the excess mortality due to HIV, the population aged over 60 years is estimated to more than double by 2030 due to lower all-cause mortality rates [16]. Cardiovascular risk factors are already prevalent among South African adults, with high levels of obesity, hypertension, and cigarette smoking [17]. In addition, HIV infection and ART have been found to be further independent risk factors for cardiovascular diseases and other age-related chronic conditions [18]. The ageing of the HIV epidemic will also have important consequences for the organization of HIV care and prevention. Treated HIV is a chronic condition interacting with and accelerating ageing. Comorbidities, interactions with other drugs, and drug toxicity complicate ART in the elderly, who often require individualized regimens and careful monitoring [18]. Furthermore, disease progression increases with age at acquiring HIV, and effectiveness of ART is lower in people initiated at an older age than at younger age [18].

The above-mentioned processes are not accounted for in the model; however, it is unlikely that they will severely affect our results. A reduced effectiveness of ART and thus increased transmission probability of HIV, coupled with the expected lower all-cause mortality [16], may result in an even more substantial increase in the number of HIV-infected elderly compared to our model predictions. On the contrary, our assumption that the full WHO treatment guidelines will be implemented in 2011 will result in a slight overestimation of the number of HIV-infected elderly since, under the current South African ART policy, only pregnant women and tuberculosis-infected patients are eligible for ART at 350 cells/μl or less, whereas, for others, the 200 cells/μl or less threshold remains for the time being. Furthermore, disease progression is generally faster in the elderly [18], but this is likely to have a limited impact on our predictions since these patients often die of other causes. Finally, we did not consider the impact of ART and HIV on the population growth in the area because long-term projections on population size and structure would require additional assumptions regarding future changes in fertility and background mortality rates which are not only influenced by HIV and ART, but also other processes such as economic growth, and political and economic stability.

We used a 92% reduction in infectivity due to ART and a factor of 3 increase in ART naive based on the best available estimates, but some argue that this might be overly optimistic [19]. If we assume an 80% reduction instead, HIV prevalence in the population aged over 50 years will increase even further to about 26% in 2040, and the total number of HIV-infected individuals aged over 50 years will have doubled by 2040 (results not shown). Also, increased survival benefits [20] will result in a further increase in the HIV prevalence (to 25% in 2040) and the total number of HIV-infected elderly (a 90% increase in 2040 compared to 2010). The proportion of HIV-infected patients aged over 50 years only changes slightly under these alternative assumptions (results not shown).

In conclusion, we show that the HIV epidemic in South Africa is at a critical turning point. Whereas the number of infections among young people will continue to decline [6], the number of HIV infections in the elderly can be expected to increase by about 50% in the next 15 years. In the near future, this group will need to be an important focus of attention, and creative solutions need to be found to alleviate further stress placed on an already overburdened health system through the increased need for specialized care, and interacting with other public health problems of an ageing population.

Back to Top | Article Outline

Acknowledgements

J.A.C.H., M.N.L., and S.Jd.V. performed the main analysis, interpreted the results and drafted the manuscript. R.B. assisted in developing the model and interpreting the results. M.L.N., F.T., T.B., and R.B. assisted in interpreting the results and drafting the manuscript.

Back to Top | Article Outline

Conflicts of interest

This work is supported by the National Institute of Health (1R01MH083539–01 to Dr M. Lurie) and grants from the Wellcome Trust to the Africa Centre for Health and Population Studies, University of KwaZulu-Natal, South Africa 082384/Z/07/Z. The funding organizations had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review or approval of the manuscript. In addition, this study is made possible by the generous support of the American people through the US Agency for International Development (USAID) and the President's Emergency Plan (PEPFAR) under the terms of Award No. 674-A-00-08-0001-00 for the Hlabisa Treatment and Care Programme. The opinions expressed herein are those of the authors and do not necessarily reflect the views of USAID or the US Government.

Back to Top | Article Outline

References

1. WHO. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2010. Geneva: World Health Organization; 2010.
2. Negin J, Cumming RG. HIV infection in older adults in sub-Saharan Africa: extrapolating prevalence from existing data. Bull World Health Organ 2010; 88:847–853.
3. Mills EJ, Rammohan A, Awofeso N. Ageing faster with AIDS in Africa. Lancet 2010 [Epub ahead of print].
4. CDC. HIV/AIDS Surveillance Report, 2008; Vol 20. Atlanta: Centers for Disease Control and Prevention; 2010. http://www.cdc.gov/hiv/surveillance/resources/reports/2008report/index.htm. [Accessed 22 October 2010]
5. Effros RB, Fletcher CV, Gebo K, Halter JB, Hazzard WR, Horne FM, et al. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 2008; 47:542–553.
6. UNAIDS. Report on the Global AIDS epidemic; 2010. http://www.unaids.org/GlobalReport/Global_report.htm. [Accessed 12 December 2010]
7. Wallrauch C, Barnighausen T, Newell M. HIV prevalence and incidence in people 50 years and older in rural South Africa. S Afr Med J 2010; 100:812–814.
8. Korenromp EL, Van Vliet C, Bakker R, De Vlas SJ, Habbema JD. HIV spread and partnership reduction for different patterns of sexual behavior: a study with the microsimulation model STDSIM. Math Pop Studies 2000; 8:135–173.
9. Orroth KK, Freeman EE, Bakker R, Buve A, Glynn JR, Boily MC, et al. Understanding the differences between contrasting HIV epidemics in east and west Africa: results from a simulation model of the Four Cities Study. Sex Transm Infect 2007; 83 (Suppl 1):i5–i16.
10. Tanser F, Hosegood V, Barnighausen T, Herbst K, Nyirenda M, Muhwava W, et al. Cohort Profile: Africa Centre Demographic Information System (ACDIS) and population-based HIV survey. Int J Epidemiol 2008; 37:956–962.
11. Cooke GS, Tanser FC, Barnighausen TW, Newell ML. Population uptake of antiretroviral treatment through primary care in rural South Africa. BMC Public Health 2010; 10:585.
12. Houlihan CF, Bland R, Mutevedzi P, Lessells RJ, Ndirangu J, Thulare H, et al.Cohort Profile: Hlabisa HIV treatment and care programme. Int J Epidemiol 2010. [Epub ahead of print]
13. Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, et al. When to start antiretroviral therapy in resource-limited settings. Ann Intern Med 2009; 151:157–166.
14. Donnell D, Baeten J, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375:2092–2098.
15. WHO. Rapid advice: antiretroviral therapy for HIV infected in adults and adolescents. Geneva: World Health Organization; 2009.
16. Tollman SM, Kahn K, Sartorius B, Collinson MA, Clark SJ, Garenne ML. Implications of mortality transition for primary healthcare in rural South Africa: a population-based surveillance study. Lancet 2008; 372:893–901.
17. Sliwa K, Wilkinson D, Hansen C, Ntyintyane L, Tibazarwa K, Becker A, et al. Spectrum of heart disease and risk factors in a black urban population in South Africa (the Heart of Soweto Study): a cohort study. Lancet 2008; 371:915–922.
18. Justice AC. HIV and aging: time for a new paradigm. Curr HIV/AIDS Rep 2010; 7:69–76.
19. Wang L, Ge Z, Luo J, Duo S, Xing G, Guo-Wei D, et al.HIV transmission risk among serodiscordant couples: a retrospective study of former plasma donors in Henan, China. J Acquir Immune Defic Syndr 2010; 55:232–238.
20. Johansson KA, Robberstad B, Norheim OF. Further benefits by early start of HIV treatment in low income countries: survival estimates of early versus deferred antiretroviral therapy. AIDS Res Ther 2010; 7:3.

Supplemental Digital Content

Back to Top | Article Outline
© 2011 Lippincott Williams & Wilkins, Inc.